Led by SoftBank Vision Fund, PICC Capital, and Morningside

XtalPi and PhoreMost sign drug discovery collaboration to discover novel inhibitors of "undruggable" targets

Combining AI Algorithms with Targeted Experiments to Solve Bottleneck Challenges in Drug Development

XtalPi team shares the timeline and preliminary results on their research of the new coronavirus.

XtalPi named as one of World's Top 20 AI Drug Development Companies

to support XtalPi’s continuous market growth and expand the application of its technology into new areas of pharmaceutical research.

Case study on how XtalPi is helping pfizer scientists predict and optimize the crystalline forms of drug candidates.

to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery

To date, XtalPi has raised over 20 million USD, making it one of the top-funded AI-powered biotechs.

This collaboration serves to explore and showcase how XtalPi’s algorithm-based solution could accelerate the drug solid-form screening and designing process.

Thanks to AWS and Spot Instances, we were able to build a flexible and scalable high-performance-computing cluster in the cloud, and reach an ideal cost efficiency.